Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio
ALS Data For Verdiperstat Expected In 2022
Executive Summary
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
You may also be interested in...
Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.
Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS
Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval.
Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start
With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.